Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

NCT01565902 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: BAF312

Sponsor

Novartis Pharmaceuticals